EVALUATION OF THE PROGNOSTIC SIGNIFICANCE OF THE INTENSITY AND FREQUENCY OF COUGH IN PATIENTS WITH INTERSTITIAL LUNG DAMAGE
Keywords:
nonspecific interstitial pneumonia, COVID-19, cough frequency, cough intensity, interstitial lung disease, systemic connective tissue diseaseAbstract
The intensity and frequency of coughing in interstitial lung disease (ILD) remain unclear. Purpose of the study. To assess the intensity and frequency of cough in nonspecific interstitial pneumonia (NsIP), interstitial lung disease in systemic connective tissue diseases (IIP-CCTD) and COVID-19 associated interstitial pneumonia (COVID-19AIP) and to study their correlation with clinical indicators. Materials and research methods. In this study, cough intensity and frequency were assessed using subjective qualitative cough assessment (cough or no cough), quantitative methods including the Listner Cough Questionnaire (LCQ-Leicester Cough Questionnaire), Visual Analogue Cough Scale (VAS), diary cough severity diary and CQLQ-cough-specific quality of life questionnaire, as well as chronic dyspnea scale and frequency scale. cough in gastroesophageal reflux disease (GERD). Correlations between cough intensity and frequency with potential predictor variables were tested using bivariate and multiple logistic regression analyses. Results. The study included: 200 patients with NSIP, 49 with IIP-MCTD and COVID-19AIP-59 patients, respectively. Patients with NSIP and COVID-19AIP had the highest cough intensity among the study groups. In patients with NSIP and COVID-19 AIP, both intensity and frequency of cough were negatively correlated with lung diffusivity. In IIP-MCTD, both intensity and frequency of cough correlated with a higher FSSG score (Frequency scale for the Symptoms of GERD). In a multivariate analysis of patients with IIP-CCTS, the FSSG score was independent and associated with both cough components. Finally, we examined the features of the differences between the intensity and frequency of cough in all three groups of patients. Patients in whom the frequency and intensity of cough prevailed over the rest of the clinical symptoms had a more pronounced deterioration in health indicators (CQLQ cough quality of life questionnaire) compared with other patients. Findings. Cough intensity was higher with NSIP and COVID-19AIP compared with IIP-MCTD. Various clinical parameters correlated with the intensity and frequency of cough depending on the subtype of IIP-MCTS. Cough frequency was strongly associated with subjective health status, compared to cough intensity. The data obtained by us in assessing the intensity and frequency of cough indicate the need to manage patients, taking into account the objective and subjective factors associated with cough.
References
Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology. 2011;16: 969–75.
Theodore AC, Tseng CH, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the scleroderma lung study. Chest. 2012;142:614–21.
Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, et al. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology. 2017;22:1592–7.
Raj AA, Birring SS. Clinical assessment of chronic cough severity. Pulm Pharmacol Ther. 2007;20:334–7.
Morice AH, Fontana GA, Belvisi MG, Birring SS, Chung KF, Dicpinigaitis PV, et al. ERS guidelines on the assessment of cough. Eur Respir J. 2007;29:1256–76.
Key AL, Holt K, Hamilton A, Smith JA, Earis JE. Objective cough frequency in idiopathic pulmonary fibrosis. Cough. 2010;6:4.
van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25:278–86.
Garner J, George PM, Renzoni E. Cough in interstitial lung disease. Pulm Pharmacol Ther. 2015;35:122–8.
Tashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, et al. Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of scleroderma lung study II. Chest. 2017;151:813–20.
Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167:962–9.
Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med. 2012;136:591– 600.
Harrison NK. Idiopathic pulmonary fibrosis: a nervous cough? Pulm Pharmacol Ther. 2004;17:347–50.
Savarino E, Bazzica M, Zentilin P, Pohl D, Parodi A, Cittadini G, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma. Am J Respir Crit Care Med. 2009;179:408–13.
Chung KF, Pavord ID. Chronic cough 1 - prevalence, pathogenesis, and causes of chronic cough. Lancet. 2008;371:1364–74.
Tobin RW, Pope CE 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1804–8.
Каримова М. М. и др. СOVID-19 O’TKAZGAN BEMORLARDA QALQONSIMON BEZ XOLATINI TAXLIL QILISH //Журнал кардиореспираторных исследований. – 2022. – Т. 3. – №. 1.
Abdurashidovna A. Z. COVID-19 YURAK QON TOMIR KASALLIKLARI BOR BEMORLARDA KECHISHI //Журнал кардиореспираторных исследований. – 2021. – Т. 2. – №. 2.
Тогаева Б. и др. COVID-19 YURAK QON TOMIR KASALLIKLARI BOR BEMORLARDA KECHISHI //Журнал кардиореспираторных исследований. – 2021. – Т. 2. – №. 2. – С. 47-50.
